受MS药物数据影响，Clene股价盘后上涨52%

Shares of Clene (NASDAQ:CLNN) rallied 52% in post-market trading Tuesday after the company presented positive Phase 2 data for its drug CNM-Au8 in the treatment of multiple sclerosis, or MS.

Clene said data from the long-term extension of its Phase 2 VISIONARY-MS study showed significant evidence of repair and remyelination across multiple paraclinical endpoints.

The company presented the data at the annual meeting of the American Academy of Neurology in Denver.